LncRNA PVT1 promotes neuroinflammation after intracerebral hemorrhage by regulating the miR-128-3p/TXNIP axis

Gong, Fanyong; Wei, Yiting

doi:10.1080/00207454.2024.2312998

Cited by 4 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In TBI, lncRNAs such as MALAT1 , NEAT1 , and H19 have been implicated in modulating neuronal apoptosis, glial activation, and blood–brain barrier integrity ( Xin and Jiang, 2017 ; Zhong et al, 2017 ; Chen Z. et al, 2019 ). In cerebral haemorrhage, lncRNAs like MIAT and PVT1 have been associated with vascular damage, haematoma resolution, and neuronal survival ( Li E. Y. et al, 2019 ; Gong and Wei, 2024 ).…”

Section: Lncrnas In Neurological Disordersmentioning

confidence: 99%

Hidden regulators: the emerging roles of lncRNAs in brain development and disease

Alammari,

Al-Hujaily,

Alshareeda

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have emerged as critical players in brain development and disease. These non-coding transcripts, which once considered as “transcriptional junk,” are now known for their regulatory roles in gene expression. In brain development, lncRNAs participate in many processes, including neurogenesis, neuronal differentiation, and synaptogenesis. They employ their effect through a wide variety of transcriptional and post-transcriptional regulatory mechanisms through interactions with chromatin modifiers, transcription factors, and other regulatory molecules. Dysregulation of lncRNAs has been associated with certain brain diseases, including Alzheimer’s disease, Parkinson’s disease, cancer, and neurodevelopmental disorders. Altered expression and function of specific lncRNAs have been implicated with disrupted neuronal connectivity, impaired synaptic plasticity, and aberrant gene expression pattern, highlighting the functional importance of this subclass of brain-enriched RNAs. Moreover, lncRNAs have been identified as potential biomarkers and therapeutic targets for neurological diseases. Here, we give a comprehensive review of the existing knowledge of lncRNAs. Our aim is to provide a better understanding of the diversity of lncRNA structure and functions in brain development and disease. This holds promise for unravelling the complexity of neurodevelopmental and neurodegenerative disorders, paving the way for the development of novel biomarkers and therapeutic targets for improved diagnosis and treatment.

show abstract

Section: Lncrnas In Neurological Disordersmentioning

confidence: 99%

Hidden regulators: the emerging roles of lncRNAs in brain development and disease

Alammari,

Al-Hujaily,

Alshareeda

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

LncRNA PVT1 Promotes Intracranial Aneurysm Development via USP10/KLF4/NLRP3 Axis‐Mediated Pyroptosis in Human Cerebral Smooth Muscle Cells

Chen,

Li,

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Our previous research identified that lncRNA PVT1 is upregulated in patients with IA. However, the precise functions of PVT1 in IA remain unclear. We compared the levels of PVT1, caspase‐3, caspase‐1, and NLRP3 in normal and IA patients. The GEO database was utilized to evaluate the expression of KLF4 and NLRP3 in IA. In vitro, we constructed transfected plasmids for silencing (si) and overexpression (oe) of PVT1 and USP10. We assessed cell apoptosis and measured the levels of IL‐18, IL‐1β, NLRP3, ASC, GSDMD‐N, cleaved‐caspase‐3, and cleaved‐caspase‐1. CHX chase, immunoprecipitation assays, and bioinformatics tools were employed to evaluate the interactions among PVT1, USP10, and KLF4. Significant differences were observed in the levels of PVT1, KLF4, NLRP3, caspase‐3, caspase‐1, and histological examinations between normal and IA patients. Compared to the oe‐NC group, the levels of IL‐18, IL‐1β, NLRP3, ASC, GSDMD‐N, cleaved‐caspase‐3, and cleaved‐caspase‐1 were significantly increased in the oe‐PVT1 and oe‐USP10 groups. The effect of oe‐USP10 was completely inhibited in the oe‐USP10+si‐PVT1 group. The RIPseq database demonstrated that PVT1 interacts with both USP10 and KLF4. The CHX chase assay showed that KLF4 interacts with both USP10 and PVT1. The RIP assay confirmed the interaction between PVT1 and USP10. The Co‐IP assay and UbiBrowser indicated that KLF4 interacts with USP10. The ChIP assay demonstrated that KLF4 interacts with NLRP3. PVT1 may play a role in the pathophysiology of IA by regulating the USP10/KLF4/NLRP3 axis‐mediated pyroptosis of HCSMCs.

show abstract

MicroRNA-based interventions in aberrant cell cycle diseases: Therapeutic strategies for cancers, central nervous system disorders and comorbidities

Tang,

Ren,

Zeng

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

LncRNA PVT1 promotes neuroinflammation after intracerebral hemorrhage by regulating the miR-128-3p/TXNIP axis

Cited by 4 publications

References 59 publications

Hidden regulators: the emerging roles of lncRNAs in brain development and disease

Hidden regulators: the emerging roles of lncRNAs in brain development and disease

LncRNA PVT1 Promotes Intracranial Aneurysm Development via USP10/KLF4/NLRP3 Axis‐Mediated Pyroptosis in Human Cerebral Smooth Muscle Cells

MicroRNA-based interventions in aberrant cell cycle diseases: Therapeutic strategies for cancers, central nervous system disorders and comorbidities

Contact Info

Product

Resources

About